You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEtodolac
Accession NumberDB00749  (APRD00067)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionEtodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.
Structure
Thumb
Synonyms
(+-)-1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid
(1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid
1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid
1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid
1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid
Étodolac
Etodolac
Etodolaco
Etodolacum
Etodolic acid
Etodolsäure
External Identifiers
  • AY 24236
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EtodolacCapsule200 mgOralAa Pharma Inc1997-08-21Not applicableCanada
EtodolacCapsule300 mgOralAa Pharma Inc1997-08-21Not applicableCanada
Gen-etodolac 200mgCapsule200 mgOralGenpharm Ulc1999-01-122009-08-05Canada
Gen-etodolac 300mgCapsule300 mgOralGenpharm Ulc1999-01-122009-08-05Canada
Novo-etodolac 200 mgCapsule200 mgOralNovopharm LimitedNot applicableNot applicableCanada
Novo-etodolac 300 mgCapsule300 mgOralNovopharm LimitedNot applicableNot applicableCanada
Nu-etodolacCapsule300 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-etodolacCapsule200 mgOralNu Pharm IncNot applicableNot applicableCanada
Taro-etodolacCapsule300 mgOralTaro Pharmaceuticals Inc2000-10-20Not applicableCanada
Taro-etodolac 200 mgCapsule200 mgOralTaro Pharmaceuticals Inc2000-10-20Not applicableCanada
Ultradol - Cap 200mgCapsule200 mgOralProcter & Gamble Pharmaceuticals Canada Inc1995-12-312002-07-23Canada
Ultradol - Cap 300mgCapsule300 mgOralProcter & Gamble Pharmaceuticals Canada Inc1995-12-312008-09-09Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EtodolacTablet, coated400 mg/1OralEon Labs, Inc.2015-04-20Not applicableUs
EtodolacTablet, film coated400 mg/1OralSTAT Rx USA LLC2003-05-01Not applicableUs
EtodolacCapsule300 mg/1OralNorthwind Pharmaceuticals, LLC2014-11-13Not applicableUs
EtodolacCapsule300 mg/1OralPd Rx Pharmaceuticals, Inc.1998-04-30Not applicableUs
EtodolacTablet, extended release400 mg/1Oralbryant ranch prepack2003-03-13Not applicableUs
EtodolacTablet, film coated400 mg/1OralTeva Pharmaceuticals Usa, Inc.1998-05-20Not applicableUs
EtodolacTablet, film coated400 mg/1OralA S Medication Solutions1998-03-11Not applicableUs
EtodolacTablet, film coated500 mg/1OralA S Medication Solutions2003-05-01Not applicableUs
EtodolacTablet, film coated, extended release600 mg/1OralTeva Pharmaceuticals USA Inc2000-08-17Not applicableUs
EtodolacTablet, film coated500 mg/1OralAidarex Pharmaceuticals LLC2009-09-09Not applicableUs
EtodolacTablet400 mg/1OralREMEDYREPACK INC.2010-10-012016-10-13Us
EtodolacTablet, film coated400 mg/1OralPhysicians Total Care, Inc.2000-01-17Not applicableUs
EtodolacTablet, film coated, extended release600 mg/1OralGolden State Medical Supply, Inc.2003-03-13Not applicableUs
EtodolacTablet, film coated, extended release400 mg/1OralCarilion Materials Management2001-02-09Not applicableUs
EtodolacCapsule300 mg/1OralApotex Corp.2003-05-01Not applicableUs
EtodolacTablet400 mg/1OralDIRECT RX2016-08-29Not applicableUs
EtodolacTablet, extended release600 mg/1OralA S Medication Solutions2003-03-13Not applicableUs
EtodolacTablet, film coated500 mg/1OralA S Medication Solutions2000-04-25Not applicableUs
EtodolacTablet, film coated500 mg/1OralApotex Corp.2003-05-01Not applicableUs
EtodolacCapsule300 mg/1OralSTAT Rx USA LLC1998-04-30Not applicableUs
EtodolacTablet, film coated400 mg/1OralAphena Pharma Solutions Tennessee, Llc1998-03-11Not applicableUs
EtodolacTablet, film coated500 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2000-04-25Not applicableUs
EtodolacTablet, film coated400 mg/1OralGolden State Medical Supply, Inc.1998-03-11Not applicableUs
EtodolacTablet, film coated, extended release400 mg/1OralDispensing Solutions, Inc.2001-02-09Not applicableUs
EtodolacTablet, extended release600 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2003-03-13Not applicableUs
EtodolacTablet, film coated400 mg/1OralPreferred Pharmaceuticals Inc.2015-08-18Not applicableUs
EtodolacTablet, extended release600 mg/1OralNorthstar Rx LLC2003-03-13Not applicableUs
EtodolacTablet, film coated500 mg/1OralPreferred Pharmaceuticals Inc.2016-06-15Not applicableUs
EtodolacCapsule200 mg/1OralKAISER FOUNDATION HOSPITALS2005-12-01Not applicableUs
EtodolacTablet, film coated400 mg/1OralLake Erie Medical DBA Quality Care Products LLC1998-05-20Not applicableUs
EtodolacCapsule300 mg/1OralUnit Dose Services1998-04-30Not applicableUs
EtodolacCapsule200 mg/1OralPhysicians Total Care, Inc.2005-04-27Not applicableUs
EtodolacTablet, film coated400 mg/1Oralbryant ranch prepack2010-04-30Not applicableUs
EtodolacTablet, coated500 mg/1OralEon Labs, Inc.2015-04-20Not applicableUs
EtodolacTablet, film coated400 mg/1OralPd Rx Pharmaceuticals, Inc.1998-05-20Not applicableUs
EtodolacCapsule200 mg/1OralTaro Pharmaceuticals U.S.A., Inc.1998-04-30Not applicableUs
EtodolacTablet, film coated500 mg/1OralLake Erie Medical DBA Quality Care Products LLC2000-04-25Not applicableUs
EtodolacTablet, film coated, extended release400 mg/1OralCadila Healthcare Limited2014-02-15Not applicableUs
EtodolacTablet, film coated500 mg/1OralTeva Pharmaceuticals Usa, Inc.2009-09-09Not applicableUs
EtodolacCapsule300 mg/1OralA S Medication Solutions2003-05-01Not applicableUs
EtodolacCapsule200 mg/1OralANI Pharmaceuticals, Inc.2015-03-09Not applicableUs
EtodolacTablet, film coated, extended release400 mg/1OralTeva Pharmaceuticals USA Inc2001-02-09Not applicableUs
EtodolacTablet, extended release500 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-06Not applicableUs
EtodolacCapsule300 mg/1OralREMEDYREPACK INC.2011-06-272016-10-21Us
EtodolacTablet, film coated500 mg/1OralPhysicians Total Care, Inc.1999-04-21Not applicableUs
EtodolacTablet, film coated400 mg/1OralREMEDYREPACK INC.2015-10-27Not applicableUs
EtodolacTablet, film coated, extended release400 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-02-15Not applicableUs
EtodolacTablet, film coated400 mg/1OralKAISER FOUNDATION HOSPITALS2016-04-22Not applicableUs
EtodolacTablet, film coated, extended release400 mg/1OralProficient Rx LP2014-02-15Not applicableUs
EtodolacTablet, film coated400 mg/1OralDispensing Solutions, Inc.1998-05-20Not applicableUs
EtodolacTablet, film coated500 mg/1OralClinical Solutions Wholesale2009-09-09Not applicableUs
EtodolacTablet, film coated400 mg/1OralA S Medication Solutions2003-05-01Not applicableUs
EtodolacTablet, film coated400 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-18Not applicableUs
EtodolacCapsule, gelatin coated300 mg/1OralRebel Distributors Corp1999-09-16Not applicableUs
EtodolacCapsule300 mg/1OralAphena Pharma Solutions Tennessee, Llc1998-04-05Not applicableUs
EtodolacTablet, film coated400 mg/1OralH.J. Harkins Company, Inc.1998-05-20Not applicableUs
EtodolacTablet, film coated500 mg/1OralGolden State Medical Supply, Inc.1998-03-12Not applicableUs
EtodolacTablet, coated400 mg/1OralPd Rx Pharmaceuticals, Inc.1997-04-11Not applicableUs
EtodolacTablet, film coated500 mg/1Oralbryant ranch prepack1999-04-21Not applicableUs
EtodolacTablet, coated500 mg/1OralPreferred Pharmaceuticals, Inc.2015-04-20Not applicableUs
EtodolacTablet, film coated400 mg/1OralA S Medication Solutions1998-05-20Not applicableUs
EtodolacTablet, coated500 mg/1OralEon Labs, Inc.1999-04-19Not applicableUs
EtodolacTablet, film coated400 mg/1OralRebel Distributors Corp2010-04-30Not applicableUs
EtodolacTablet, film coated, extended release500 mg/1OralUnit Dose Services2010-12-30Not applicableUs
EtodolacTablet, film coated400 mg/1OralBlenheim Pharmacal, Inc.2013-10-08Not applicableUs
EtodolacTablet, film coated400 mg/1OralPd Rx Pharmaceuticals, Inc.2003-05-01Not applicableUs
EtodolacCapsule300 mg/1OralTaro Pharmaceuticals U.S.A., Inc.1998-04-30Not applicableUs
EtodolacCapsule200 mg/1OralGolden State Medical Supply, Inc.1998-04-05Not applicableUs
EtodolacTablet, film coated, extended release500 mg/1OralCadila Healthcare Limited2014-02-15Not applicableUs
EtodolacTablet, extended release400 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2003-03-13Not applicableUs
EtodolacTablet, film coated500 mg/1OralA S Medication Solutions2009-09-09Not applicableUs
EtodolacCapsule300 mg/1OralANI Pharmaceuticals, Inc.2015-02-01Not applicableUs
EtodolacTablet, film coated, extended release500 mg/1OralTeva Pharmaceuticals USA Inc2000-08-11Not applicableUs
EtodolacCapsule300 mg/1OralLake Erie Medical & Surgical Supply DBA Qualtiy Care Products LLC2012-03-06Not applicableUs
EtodolacTablet, film coated400 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-19Not applicableUs
EtodolacCapsule300 mg/1OralPhysicians Total Care, Inc.2010-03-31Not applicableUs
EtodolacTablet500 mg/1OralDIRECT RX2014-01-01Not applicableUs
EtodolacTablet, film coated, extended release500 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-02-15Not applicableUs
EtodolacTablet, extended release400 mg/1OralNorthstar Rx LLC2003-03-13Not applicableUs
EtodolacTablet, film coated400 mg/1OralProficient Rx LP2003-05-01Not applicableUs
EtodolacCapsule200 mg/1OralAphena Pharma Solutions Tennessee, Llc1998-04-05Not applicableUs
EtodolacTablet, film coated, extended release500 mg/1OralPhysicians Total Care, Inc.2005-01-20Not applicableUs
EtodolacTablet, film coated, extended release400 mg/1OralGolden State Medical Supply, Inc.2003-03-13Not applicableUs
EtodolacTablet, film coated400 mg/1OralRed Pharm Drug Inc.2008-12-01Not applicableUs
EtodolacTablet, film coated400 mg/1OralClinical Solutions Wholesale1998-03-11Not applicableUs
EtodolacTablet, film coated400 mg/1OralA S Medication Solutions2003-05-01Not applicableUs
EtodolacTablet, film coated400 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-17Not applicableUs
EtodolacTablet, film coated400 mg/1OralRebel Distributors Corp1998-03-11Not applicableUs
EtodolacCapsule300 mg/1OralRebel Distributors Corp2010-03-31Not applicableUs
EtodolacTablet500 mg/1OralNorthwind Pharmaceuticals, LLC2014-10-29Not applicableUs
EtodolacTablet, coated500 mg/1OralPd Rx Pharmaceuticals, Inc.1999-04-19Not applicableUs
EtodolacTablet, film coated, extended release500 mg/1Oralbryant ranch prepack2010-12-30Not applicableUs
EtodolacTablet, coated400 mg/1OralAmerican Health Packaging2016-02-01Not applicableUs
EtodolacTablet, coated400 mg/1OralA S Medication Solutions1997-04-112017-12-31Us
EtodolacTablet, film coated400 mg/1OralDIRECT RX2014-01-01Not applicableUs
EtodolacTablet, coated400 mg/1OralEon Labs, Inc.1997-04-11Not applicableUs
EtodolacTablet400 mg/1OralSTAT Rx USA LLC1998-03-11Not applicableUs
EtodolacTablet, film coated500 mg/1OralAphena Pharma Solutions Tennessee, Llc1998-03-12Not applicableUs
EtodolacTablet, film coated400 mg/1OralTaro Pharmaceuticals U.S.A., Inc.1998-03-11Not applicableUs
EtodolacCapsule300 mg/1OralGolden State Medical Supply, Inc.1998-04-05Not applicableUs
EtodolacTablet, film coated, extended release600 mg/1OralCadila Healthcare Limited2014-02-15Not applicableUs
EtodolacTablet, extended release500 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2003-03-13Not applicableUs
EtodolacTablet, film coated, extended release600 mg/1OralA S Medication Solutions2014-02-15Not applicableUs
EtodolacTablet, film coated400 mg/1OralApotex Corp.2003-05-01Not applicableUs
EtodolacTablet, film coated400 mg/1OralNu Care Pharmaceuticals, Inc.2003-05-01Not applicableUs
EtodolacTablet, film coated400 mg/1OralKAISER FOUNDATION HOSPITALS2015-01-13Not applicableUs
EtodolacTablet, film coated400 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1998-03-11Not applicableUs
EtodolacTablet, film coated400 mg/1OralUnit Dose Services1998-03-11Not applicableUs
EtodolacTablet, film coated, extended release600 mg/1OralPhysicians Total Care, Inc.2011-09-13Not applicableUs
EtodolacTablet, film coated, extended release600 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-02-15Not applicableUs
EtodolacTablet, extended release500 mg/1OralNorthstar Rx LLC2003-03-13Not applicableUs
EtodolacTablet, film coated400 mg/1OralAidarex Pharmaceuticals LLC1998-05-20Not applicableUs
EtodolacCapsule300 mg/1OralREMEDYREPACK INC.2010-10-062016-10-13Us
EtodolacTablet, film coated, extended release400 mg/1OralPhysicians Total Care, Inc.2005-01-20Not applicableUs
EtodolacTablet, film coated, extended release500 mg/1OralGolden State Medical Supply, Inc.2003-03-13Not applicableUs
EtodolacTablet, coated400 mg/1OralAmerican Health Packaging2014-09-222016-03-31Us
EtodolacCapsule200 mg/1OralApotex Corp.2003-05-01Not applicableUs
EtodolacTablet, film coated500 mg/1OralA S Medication Solutions2003-05-01Not applicableUs
EtodolacCapsule300 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-17Not applicableUs
LodineTablet, film coated400 mg/1OralSallus Laboratories, Llc2016-09-01Not applicableUs
LodineCapsule, gelatin coated300 mg/1Oralbryant ranch prepack2009-06-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BodopineYuan Chou
DolaritDrogsan
DolchisKorea United Pharm
DolocUnifarma
DualganITF
EccoxolacMeda
Edolar FortPfizer
EdopainIncepta
Edopain ERIncepta
ElacRoyal
ElderinLek
EricU.C. Pharma
EsodaxMünir Sahin
ETLSenton
EtodinNobel
Etodin FortUlkar
EtodolYuhan
EtodonShinlon
EtoflamStandard Chem
Etol FortNobel
EtolacAlkaloid
EtomaxIpca
Etomax-ERIpca
EtonoxCharoen Bhaesaj
EtopanWinthrop Pharmaceuticals
EtopinU-Liang
Lodine XLWyeth
Brand mixturesNot Available
SaltsNot Available
Categories
UNII2M36281008
CAS number41340-25-4
WeightAverage: 287.3535
Monoisotopic: 287.152143543
Chemical FormulaC17H21NO3
InChI KeyNNYBQONXHNTVIJ-UHFFFAOYSA-N
InChI
InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)
IUPAC Name
2-{1,8-diethyl-1H,3H,4H,9H-pyrano[3,4-b]indol-1-yl}acetic acid
SMILES
CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
Pharmacology
IndicationFor acute and long-term management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain.
Structured Indications
PharmacodynamicsEtodolac is an anti-inflammatory agent with analgesic and antipyretic properties. It is used to treat osteoarthritis, rheumatoid arthritis and control acute pain. The therapeutic effects of etodolac are achieved via inhibition of the synthesis of prostaglandins involved in fever, pain, swelling and inflammation. Etodolac is administered as a racemate. As with other NSAIDs, the S-form has been shown to be active while the R-form is inactive. Both enantiomers are stable and there is no evidence of R- to S- conversion in vivo.
Mechanism of actionSimilar to other NSAIDs, the anti-inflammatory effects of etodolac result from inhibition of the enzyme cycooxygenase (COX). This decreases the synthesis of peripheral prostaglandins involved in mediating inflammation. Etodolac binds to the upper portion of the COX enzyme active site and prevents its substrate, arachidonic acid, from entering the active site. Etodolac was previously thought to be a non-selective COX inhibitor, but it is now known to be 5 – 50 times more selective for COX-2 than COX-1. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Retinoic acid receptor RXR-alphaProteinunknown
other
HumanP19793 details
Related Articles
AbsorptionBased on mass balance studies, the systemic bioavailability of etodolac from either the tablet or capsule formulation is at least 80%.
Volume of distribution
  • 390 mL/kg
Protein binding> 99% bound, primarily to albumin
Metabolism

Etodolac is extensively metabolized in the liver. Renal elimination of etodolac and its metabolites is the primary route of excretion (72%). Metabolites found in urine (with percents of the administered dose) are: unchanged etodolac (1%), etodolac glucuronide (13%), hydroxylated metabolites (6-, 7-, and 8-OH; 5%), hydroxylated metabolite glucuronides (20%), and unidentified metabolites (33%). Fecal excretion accounts for 16% of its elimination.

SubstrateEnzymesProduct
Etodolac
6-HydroxyetodolacDetails
Etodolac
7-HydroxyetodolacDetails
Etodolac
Etodolac acyl glucuronideDetails
Route of eliminationIt is not known whether etodolac is excreted in human milk; however, based on its physical-chemical properties, excretion into breast milk is expected. Etodolac is extensively metabolized in the liver. The hydroxylated-etodolac metabolites undergo further glucuronidation followed by renal excretion and partial elimination in the feces (16% of dose). Approximately 1% of a etodolac dose is excreted unchanged in the urine with 72% of the dose excreted into urine as parent drug plus metabolite.
Half lifeTerminal t1/2, 7.3 ± 4.0 hours. Distribution t1/2, 0.71 ± 0.50 hours
Clearance
  • Oral cl=49.1 mL/h/kg [Normal healthy adults]
  • Oral cl=49.4 mL/h/kg [Healthy males (18-65 years)]
  • Oral cl=35.7 mL/h/kg [Healthy females (27-65 years)]
  • Oral cl=45.7 mL/h/kg [Eldery (>65 years)]
  • Oral cl=58.3 mL/h/kg [Renal impairement (46-73 years)]
  • Oral cl=42.0 mL/h/kg [Hepatic impairement (34-60 years)]
ToxicitySelective COX-2 inhibitors have been associated with increased risk of serious cardiovascular events (e.g. myocardial infarction, stroke) in some patients. Current data is insufficient to assess the cardiovascular risk of etodolac. Etodolac may increase blood pressure and/or cause fluid retention and edema. Risk of GI toxicity including bleeding, ulceration and perforation. Risk of direct renal injury, including renal papillary necrosis. Anaphylactoid and serious skin reactions (e.g. exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported. Common adverse events include abdominal pain, constipation, diarrhea, dyspepsia, flatulence, GI bleeding, GI perforation, nausea, peptic ulcer, vomiting, renal function abnormalities, anemia, dizziness, edema, liver function test abnormalities, headache, prolonged bleeding time, pruritus, rash, tinnitus. Symptoms of overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Etodolac Action PathwayDrug actionSMP00084
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Etodolac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Etodolac is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Etodolac is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Etodolac is combined with 5-androstenedione.Experimental, Illicit
AbciximabEtodolac may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Etodolac can be decreased when combined with Abiraterone.Approved
AcebutololEtodolac may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Etodolac.Approved
AcenocoumarolEtodolac may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Etodolac.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etodolac.Approved, Vet Approved
AclarubicinEtodolac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Etodolac.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Etodolac is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Etodolac is combined with Alendronic acid.Approved
AliskirenEtodolac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololEtodolac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Etodolac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Etodolac is combined with Amcinonide.Approved
AmikacinEtodolac may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideEtodolac may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Etodolac can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinEtodolac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodEtodolac may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Etodolac is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Etodolac.Investigational
annamycinEtodolac may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Etodolac.Approved
Antithrombin III humanEtodolac may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Etodolac may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanEtodolac may increase the anticoagulant activities of Apixaban.Approved
ApramycinEtodolac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Etodolac.Approved, Investigational
AprepitantThe metabolism of Etodolac can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinEtodolac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinEtodolac may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanEtodolac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololEtodolac may decrease the antihypertensive activities of Arotinolol.Approved
AtenololEtodolac may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Etodolac.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Etodolac.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etodolac.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Etodolac.Approved, Investigational
BazedoxifeneEtodolac may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminEtodolac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Etodolac is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololEtodolac may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Etodolac.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etodolac.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Etodolac.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Etodolac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Betamethasone.Approved, Vet Approved
BetaxololEtodolac may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Etodolac.Investigational
BevantololEtodolac may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Etodolac.Approved, Investigational
BisoprololEtodolac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinEtodolac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololEtodolac may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etodolac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Etodolac.Investigational
BucindololEtodolac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Etodolac is combined with Budesonide.Approved
BufuralolEtodolac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideEtodolac may decrease the diuretic activities of Bumetanide.Approved
BupranololEtodolac may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Etodolac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Etodolac.Experimental
CapecitabineThe metabolism of Etodolac can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Etodolac.Approved
CarbamazepineThe metabolism of Etodolac can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etodolac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Etodolac.Approved, Vet Approved, Withdrawn
CarteololEtodolac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolEtodolac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Etodolac.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etodolac.Approved, Investigational
CeliprololEtodolac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Etodolac can be increased when it is combined with Ceritinib.Approved
CertoparinEtodolac may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etodolac.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etodolac.Approved, Vet Approved
ChlorotrianiseneEtodolac may increase the thrombogenic activities of Chlorotrianisene.Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etodolac.Approved
CholecalciferolThe metabolism of Etodolac can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Etodolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Etodolac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etodolac.Approved
CinoxacinEtodolac may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinEtodolac may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CitalopramCitalopram may increase the antiplatelet activities of Etodolac.Approved
Citric AcidEtodolac may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Etodolac is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Etodolac is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Etodolac is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Etodolac.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Etodolac.Vet Approved
ClotrimazoleThe metabolism of Etodolac can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Etodolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Etodolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensEtodolac may increase the thrombogenic activities of Conjugated Equine Estrogens.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Etodolac is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Etodolac.Investigational
CyclosporineEtodolac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Etodolac can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Etodolac.Investigational
Dabigatran etexilateEtodolac may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Etodolac can be decreased when it is combined with Dabrafenib.Approved
DalteparinEtodolac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidEtodolac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Etodolac.Investigational
DaunorubicinEtodolac may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Etodolac is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Etodolac is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Etodolac can be decreased when combined with Delavirdine.Approved
DesirudinEtodolac may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Etodolac is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Etodolac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Etodolac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Etodolac.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Etodolac is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Etodolac.Approved
DextranEtodolac may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Etodolac may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Etodolac may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Etodolac may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Etodolac.Approved, Vet Approved
DicoumarolEtodolac may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolEtodolac may increase the thrombogenic activities of Dienestrol.Approved
DiethylstilbestrolEtodolac may increase the thrombogenic activities of Diethylstilbestrol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etodolac.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Etodolac is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Etodolac.Approved
DihydrostreptomycinEtodolac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Etodolac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Etodolac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Etodolac.Approved
DoxorubicinEtodolac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneEtodolac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Etodolac.Approved
DuloxetineDuloxetine may increase the antiplatelet activities of Etodolac.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Etodolac.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Etodolac.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Etodolac.Investigational
Edetic AcidEtodolac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEtodolac may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Etodolac can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Etodolac.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Etodolac.Approved
EnoxacinEtodolac may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinEtodolac may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Etodolac.Approved
EpirubicinEtodolac may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneEtodolac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etodolac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etodolac.Approved
EquileninThe risk or severity of adverse effects can be increased when Etodolac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Etodolac is combined with Equilin.Approved
EscitalopramEscitalopram may increase the antiplatelet activities of Etodolac.Approved, Investigational
EsmololEtodolac may decrease the antihypertensive activities of Esmolol.Approved
EstradiolEtodolac may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
EstriolEtodolac may increase the thrombogenic activities of Estriol.Approved, Vet Approved
EstroneEtodolac may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Etodolac is combined with Estrone sulfate.Approved
Etacrynic acidEtodolac may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Etodolac.Approved, Investigational
Ethinyl EstradiolEtodolac may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateEtodolac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Etodolac is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Etodolac.Approved
EtoperidoneEtoperidone may increase the antiplatelet activities of Etodolac.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etodolac is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Etodolac can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Etodolac.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Etodolac.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Etodolac.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etodolac.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Etodolac.Vet Approved
FleroxacinEtodolac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Etodolac.Approved, Withdrawn
FloxuridineThe metabolism of Etodolac can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Etodolac is combined with fluasterone.Investigational
FluconazoleThe metabolism of Etodolac can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Fludrocortisone.Approved
FluindioneEtodolac may increase the anticoagulant activities of Fluindione.Investigational
FlumequineEtodolac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Etodolac is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Etodolac.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Etodolac can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Etodolac.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Etodolac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Etodolac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etodolac.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Etodolac can be decreased when combined with Fluvastatin.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Etodolac.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Etodolac.Approved, Nutraceutical, Vet Approved
FondaparinuxEtodolac may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumEtodolac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Etodolac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Etodolac is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etodolac.Approved
FosphenytoinThe metabolism of Etodolac can be increased when combined with Fosphenytoin.Approved
FramycetinEtodolac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideEtodolac may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateEtodolac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinEtodolac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinEtodolac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Etodolac.Approved, Withdrawn
GemfibrozilThe metabolism of Etodolac can be decreased when combined with Gemfibrozil.Approved
GemifloxacinEtodolac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinEtodolac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinEtodolac may increase the thrombogenic activities of Genistein.Investigational
GentamicinEtodolac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AEtodolac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinEtodolac may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Etodolac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Etodolac is combined with HE3286.Investigational
HeparinEtodolac may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolEtodolac may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Etodolac.Investigational
HirulogEtodolac may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Etodolac.Investigational
HydralazineEtodolac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etodolac.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etodolac.Approved
Hygromycin BEtodolac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Etodolac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Etodolac.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Etodolac.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Etodolac.Approved
IdarubicinEtodolac may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxEtodolac may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etodolac.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Etodolac.Investigational
IndalpineIndalpine may increase the antiplatelet activities of Etodolac.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etodolac.Approved
IndenololEtodolac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Etodolac can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etodolac.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Etodolac.Withdrawn
INNO-206Etodolac may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Etodolac can be decreased when combined with Irbesartan.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Etodolac.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Etodolac is combined with Istaroxime.Investigational
KanamycinEtodolac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Etodolac.Experimental
KetoconazoleThe metabolism of Etodolac can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Etodolac.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Etodolac.Approved
LabetalolEtodolac may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Etodolac.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Etodolac.Approved, Investigational
LepirudinEtodolac may increase the anticoagulant activities of Lepirudin.Approved
LevobunololEtodolac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinEtodolac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Etodolac.Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Etodolac.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Etodolac.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Etodolac.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Etodolac.Approved
LomefloxacinEtodolac may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Etodolac.Approved
LosartanThe metabolism of Etodolac can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Etodolac can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Etodolac.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Etodolac.Approved, Investigational
LumacaftorThe serum concentration of Etodolac can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Etodolac is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Etodolac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etodolac.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Etodolac.Approved
ME-609The risk or severity of adverse effects can be increased when Etodolac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etodolac.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Etodolac.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Etodolac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Etodolac.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Etodolac.Approved
MestranolEtodolac may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Etodolac.Withdrawn
MethallenestrilEtodolac may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Etodolac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etodolac.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Methylprednisolone.Approved, Vet Approved
MetipranololEtodolac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etodolac.Approved
MetoprololEtodolac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideEtodolac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneThe serum concentration of Etodolac can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Etodolac.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Etodolac.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Etodolac.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Etodolac.Approved
MometasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Etodolac.Approved
MoxifloxacinEtodolac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etodolac.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etodolac.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Etodolac.Approved
NadololEtodolac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinEtodolac may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Etodolac.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Etodolac.Approved
Nalidixic AcidEtodolac may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Etodolac.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Etodolac is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Etodolac.Investigational
NeamineEtodolac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneNefazodone may increase the antiplatelet activities of Etodolac.Approved, Withdrawn
NemonoxacinEtodolac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinEtodolac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Etodolac.Approved
NetilmicinEtodolac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NicardipineThe metabolism of Etodolac can be decreased when combined with Nicardipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Etodolac.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Etodolac.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Etodolac.Investigational
NorfloxacinEtodolac may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinEtodolac may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Etodolac is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etodolac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etodolac.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etodolac.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Etodolac is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Etodolac.Investigational
OmeprazoleThe metabolism of Etodolac can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Etodolac.Vet Approved
OtamixabanEtodolac may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etodolac.Approved
OxprenololEtodolac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etodolac.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Etodolac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Etodolac is combined with Parecoxib.Approved
ParomomycinEtodolac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Etodolac.Approved, Investigational
PazufloxacinEtodolac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinEtodolac may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololEtodolac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateEtodolac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Etodolac.Approved
PhenindioneEtodolac may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Etodolac can be increased when combined with Phenobarbital.Approved
PhenprocoumonEtodolac may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Etodolac.Approved, Vet Approved
PhenytoinThe metabolism of Etodolac can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etodolac.Approved, Investigational
PindololEtodolac may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinEtodolac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideEtodolac may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Etodolac.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etodolac.Approved, Investigational
PlicamycinEtodolac may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
Polyestradiol phosphateEtodolac may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Etodolac.Approved
PractololEtodolac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Etodolac.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Etodolac is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Etodolac is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Etodolac can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Etodolac can be increased when it is combined with Probenecid.Approved
PromestrieneEtodolac may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Etodolac.Approved
PropranololEtodolac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Etodolac.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Etodolac.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Etodolac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Etodolac.Vet Approved
Protein CEtodolac may increase the anticoagulant activities of Protein C.Approved
Protein S humanEtodolac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEtodolac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinEtodolac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Etodolac.Investigational
PuromycinEtodolac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Etodolac can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Etodolac.Approved, Investigational
QuinestrolEtodolac may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Etodolac.Approved
QuinineThe metabolism of Etodolac can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Etodolac.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etodolac.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Etodolac.Experimental, Investigational
ReviparinEtodolac may increase the anticoagulant activities of Reviparin.Approved
RibostamycinEtodolac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe metabolism of Etodolac can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Etodolac can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Etodolac is combined with Risedronate.Approved, Investigational
RivaroxabanEtodolac may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Etodolac.Investigational, Withdrawn
RosoxacinEtodolac may increase the neuroexcitatory activities of Rosoxacin.Approved
S EquolEtodolac may increase the thrombogenic activities of S Equol.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Etodolac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Etodolac.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Etodolac.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Etodolac.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etodolac.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Etodolac.Investigational
SecobarbitalThe metabolism of Etodolac can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolEtodolac may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Etodolac.Approved, Investigational
SertralineSertraline may increase the antiplatelet activities of Etodolac.Approved
SildenafilThe metabolism of Etodolac can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinEtodolac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SorafenibThe metabolism of Etodolac can be decreased when combined with Sorafenib.Approved, Investigational
SotalolEtodolac may decrease the antihypertensive activities of Sotalol.Approved
SP1049CEtodolac may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinEtodolac may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinEtodolac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Etodolac.Approved
SpironolactoneEtodolac may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Etodolac.Investigational
StreptomycinEtodolac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinEtodolac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Etodolac can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Etodolac can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etodolac.Approved
SulfisoxazoleThe metabolism of Etodolac can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Etodolac.Approved
SulodexideEtodolac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Etodolac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Etodolac.Approved, Withdrawn
Synthetic Conjugated Estrogens, AEtodolac may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BEtodolac may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusEtodolac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Etodolac.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Etodolac.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Etodolac.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Etodolac is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Etodolac is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etodolac.Approved, Investigational
TemafloxacinEtodolac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Etodolac.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Etodolac is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etodolac.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Etodolac.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Etodolac.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etodolac.Approved
TiboloneEtodolac may increase the thrombogenic activities of Tibolone.Approved
TicagrelorThe metabolism of Etodolac can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Etodolac can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Etodolac is combined with Tiludronate.Approved, Vet Approved
TimololEtodolac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Etodolac.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Etodolac is combined with Tixocortol.Approved
TobramycinEtodolac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Etodolac can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Etodolac.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etodolac.Approved
TorasemideEtodolac may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Etodolac.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Etodolac.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etodolac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etodolac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneEtodolac may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etodolac.Approved, Vet Approved
TrimethoprimThe metabolism of Etodolac can be decreased when combined with Trimethoprim.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Etodolac.Approved
TrovafloxacinEtodolac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Etodolac.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Etodolac.Investigational, Withdrawn
Valproic AcidThe metabolism of Etodolac can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinEtodolac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Etodolac can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Etodolac.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Etodolac.Approved
VoriconazoleThe metabolism of Etodolac can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinEtodolac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranEtodolac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Etodolac may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Etodolac can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etodolac.Approved
ZeranolEtodolac may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Etodolac.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Etodolac.Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Etodolac is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Etodolac.Withdrawn
ZorubicinEtodolac may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Avoid alcohol.
  • Food increases the peak plasma concentration of extended-release tablets with no effect on extent of absorption.
  • Food increases the time to peak concentration of regular release oral formulations by 1.4 to 3.8 hours with no effect on extent of absorption.
  • Take with food to reduce gastric irritation.
References
Synthesis Reference

Christopher A. Demerson, Leslie G. Humber, “Process for preparing 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, etodolac.” U.S. Patent US4585877, issued May, 1977.

US4585877
General ReferencesNot Available
External Links
ATC CodesM01AB08
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (290 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9971
Blood Brain Barrier+0.9065
Caco-2 permeable+0.5726
P-glycoprotein substrateSubstrate0.7462
P-glycoprotein inhibitor INon-inhibitor0.9242
P-glycoprotein inhibitor IINon-inhibitor0.8988
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8545
CYP450 2D6 substrateNon-substrate0.7567
CYP450 3A4 substrateNon-substrate0.5
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6904
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9453
BiodegradationNot ready biodegradable0.9835
Rat acute toxicity3.4536 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9808
hERG inhibition (predictor II)Non-inhibitor0.7763
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Aaipharma llc
  • Apotex inc
  • Endo pharmaceuticals inc
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Taro pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Wyeth pharmaceuticals inc
  • Point holdings inc
  • Watson laboratories inc florida
  • Actavis elizabeth llc
  • Apotex inc etobicoke site
  • Mylan laboratories inc
  • Ranbaxy laboratories ltd
Packagers
Dosage forms
FormRouteStrength
CapsuleOral200 mg
CapsuleOral200 mg/1
CapsuleOral300 mg/1
CapsuleOral300 mg
Capsule, gelatin coatedOral300 mg/1
TabletOral400 mg/1
TabletOral500 mg/1
Tablet, coatedOral400 mg/1
Tablet, coatedOral500 mg/1
Tablet, extended releaseOral400 mg/1
Tablet, extended releaseOral500 mg/1
Tablet, extended releaseOral600 mg/1
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral500 mg/1
Tablet, film coated, extended releaseOral400 mg/1
Tablet, film coated, extended releaseOral500 mg/1
Tablet, film coated, extended releaseOral600 mg/1
Prices
Unit descriptionCostUnit
Etodolac CR 600 mg 24 Hour tablet2.76USD tablet
Lodine 400 mg tablet2.65USD tablet
Lodine 500 mg tablet1.8USD tablet
Etodolac CR 500 mg 24 Hour tablet1.6USD tablet
Etodolac 500 mg tablet1.52USD tablet
Etodolac 400 mg tablet1.5USD tablet
Etodolac CR 400 mg 24 Hour tablet1.46USD tablet
Etodolac 300 mg capsule1.31USD capsule
Apo-Etodolac 200 mg Capsule0.8USD capsule
Apo-Etodolac 300 mg Capsule0.8USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point146.5 °CPhysProp
water solubility16 mg/LNot Available
logP2.5Not Available
pKa4.65Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0392 mg/mLALOGPS
logP3.39ALOGPS
logP3.44ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)4.73ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.32 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity81.16 m3·mol-1ChemAxon
Polarizability31.94 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indolyl carboxylic acids and derivatives. These are compounds containing a carboxylic acid chain (of at least 2 carbon atoms) linked to an indole ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassIndolyl carboxylic acids and derivatives
Direct ParentIndolyl carboxylic acids and derivatives
Alternative Parents
Substituents
  • Indolyl carboxylic acid derivative
  • Indole
  • Benzenoid
  • Heteroaromatic compound
  • Pyrrole
  • Oxacycle
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Dialkyl ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Chen WS, Liu JH, Wei SJ, Liu JM, Hong CY, Yang WK: Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor. Cancer Sci. 2003 Mar;94(3):253-8. [PubMed:12824918 ]
  2. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK: Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer. 2001 Mar 15;91(6):894-9. [PubMed:11275997 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  4. Kusuhara H, Komatsu H, Sumichika H, Sugahara K: Reactive oxygen species are involved in the apoptosis induced by nonsteroidal anti-inflammatory drugs in cultured gastric cells. Eur J Pharmacol. 1999 Nov 3;383(3):331-7. [PubMed:10594327 ]
  5. Svendsen KB, Bech JN, Sorensen TB, Pedersen EB: A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol. 2000 Aug;56(5):383-8. [PubMed:11009046 ]
  6. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Campbell NB, Jones SL, Blikslager AT: The effects of cyclo-oxygenase inhibitors on bile-injured and normal equine colon. Equine Vet J. 2002 Jul;34(5):493-8. [PubMed:12358053 ]
  2. Glaser K, Sung ML, O'Neill K, Belfast M, Hartman D, Carlson R, Kreft A, Kubrak D, Hsiao CL, Weichman B: Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol. 1995 Jul 25;281(1):107-11. [PubMed:8566109 ]
  3. Hirate K, Uchida A, Ogawa Y, Arai T, Yoda K: Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors. Neurosci Res. 2006 Apr;54(4):288-94. Epub 2006 Feb 13. [PubMed:16473424 ]
  4. Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Leger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Therien M, Wang Z, Webb JK, Wong E, Chan CC, et al.: Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17. [PubMed:9146894 ]
  5. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Zinc ion binding
Specific Function:
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXR...
Gene Name:
RXRA
Uniprot ID:
P19793
Molecular Weight:
50810.835 Da
References
  1. Kolluri SK, Corr M, James SY, Bernasconi M, Lu D, Liu W, Cottam HB, Leoni LM, Carson DA, Zhang XK: The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2525-30. Epub 2005 Feb 7. [PubMed:15699354 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein kinase c binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A10
Uniprot ID:
Q9HAW8
Molecular Weight:
59809.075 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Mignot I, Presle N, Lapicque F, Monot C, Dropsy R, Netter P: Albumin binding sites for etodolac enantiomers. Chirality. 1996;8(3):271-80. [PubMed:8777148 ]
  2. Muller N, Lapicque F, Monot C, Payan E, Dropsy R, Netter P: Stereoselective binding of etodolac to human serum albumin. Chirality. 1992;4(4):240-6. [PubMed:1389961 ]
  3. Smith PC, Song WQ, Rodriguez RJ: Covalent binding of etodolac acyl glucuronide to albumin in vitro. Drug Metab Dispos. 1992 Nov-Dec;20(6):962-5. [PubMed:1362954 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23